IPI1/NIVO3

Phase 3Small molecule

VVastra Gotaland Region

IPI1/NIVO3 is one of 26 small molecule programs targeting Uveal Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uveal MelanomaRecruiting

Uveal MelanomaPhase 3

Recruiting

Competition

Competitive Landscape

27 competitors in Uveal Melanoma

#DrugCompanyPhaseTrials

Afinitor

Yervoy

12 3

Opdivo

Bristol-Myers Squibb

Phase 3

9 4

Alkeran

AApotex Inc.

Approved

1 5

Signifor

RRECORDATI GROUP

Approved

—6

Xalkori

PPrism Pharmaceuticals

Phase 3

3 7

Mekinist

Novartis

Phase 2

2 8

KIMMTRAK

IImmunocore Ltd

Phase 3

5 9

Mektovi

Pfizer

Phase 2

1 10

Libtayo

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 3Recruiting

Uveal Melanoma

NCT06519266

Clinical

Trials by Indication[1]

Uveal Melanoma1 trial

PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases

Recruiting·VVastra Gotaland Region·Phase 3·NCT06519266·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IPI1/NIVO3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IPI1/NIVO3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IPI1/NIVO3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vastra Gotaland Region company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVastra Gotaland Region

IPI1/NIVO3

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Uveal Melanoma1 trial

References

Drug Info

Quick Facts

Related News